The enhanced activity of the cardiac Na + /H + exchanger (NHE-1) after myocardial stretch is considered a key step of the intracellular signaling pathway leading to the slow force response to stretch as well as an early signal for the development of cardiac hypertrophy. We propose that the chain of events triggered by stretch begins with the release of small amounts of Angiotensin II (Ang II)/endothelin (ET) and ends with the increase in intracellular Ca 2+ concentration ([Ca 2+ ] i ) through the Na + /Ca 2+ exchanger in reverse mode (NCX rev ), which triggers cardiac hypertrophy by activation of widely recognized Ca 2+ -dependent intracellular signaling pathways.
ABSTRACT
The enhanced activity of the cardiac Na + /H + exchanger (NHE-1) after myocardial stretch is considered a key step of the intracellular signaling pathway leading to the slow force response to stretch as well as an early signal for the development of cardiac hypertrophy. We propose that the chain of events triggered by stretch begins with the release of small amounts of Angiotensin II (Ang II)/endothelin (ET) and ends with the increase in intracellular Ca 2+ concentration ([Ca 2+ ] i ) through the Na + /Ca 2+ exchanger in reverse mode (NCX rev ), which triggers cardiac hypertrophy by activation of widely recognized Ca 2+ -dependent intracellular signaling pathways.
INTRODUCTION
During the last decade a substantial part of our own studies were addressed to identify the intracellular signaling triggered by myocardial stretch. In this regard, we have provided convincing evidence that myocardial stretch elicits an autocrine/paracrine loop that involves a sequential release of preformed Ang II and ET, and ends with an increase in contractility induced by Ca 2+ influx (1-6). Furthermore, we have proposed that an enhanced activation of NHE-1 is a key factor in this signaling pathway by increasing intracellular Na + concentration ([Na + ] i ), which drives the NCX rev thus increasing Ca 2+ transient and contractility. The question as to why this mechanism should be connected to the development of myocardial hypertrophy appears to be answered by the fact that an enhanced activity of NHE-1 is detected in several models of cardiac hypertrophy where specific NHE-1 blockade regresses cardiac hypertrophy effectively (7-38).
This review will present previously published data by our own and other laboratories supporting the notion that early intracellular signals triggered after myocardial stretch may conceivably lead to cardiac hypertrophy.
STRETCHING ADULT MYOCARDIUM
In 1998 Bluhm et al. exchanger (NCX). However, the mechanism by which the increase in [Na + ] i takes place was not proposed. Since the NHE-1 is an important entry pathway in cardiomyocytes, the possible role played by the exchanger was analyzed.
NHE-1 AND MYOCARDIAL STRETCH
The finding of a stretch-induced myocardial alkalization in cat papillary muscles bathed with a bicarbonate-free medium was the first piece of evidence provided by our laboratory about the main role played by NHE-1 in the myocardial response to stretch (1). The absence of bicarbonate from the medium allowed us to analyze the role of NHE-1 without the influence of bicarbonate-dependent intracellular pH (pH i )-regulatory mechanisms. The stretch-induced myocardial alkalization was suppressed by either Ang II type 1 (AT 1 ) or ET type A (ET A ) receptors blockade, suggesting the involvement of these receptors in the stretch-induced activation of NHE-1 (1). In accordance with this, the release of Ang II after stretching cultured neonatal cardiomyocytes was initially reported by Sadoshima and co-authors (40), who showed that the addition of surrounding medium from stretched to non-stretched cardiomyocytes promoted hypertrophy, and that Ang II was the autocrine/paracrine mediator of this effect. Contemporarily, Ito et al. (41) found in the same preparation that Ang II promotes the release/formation of ET-1, demonstrating that ET-1 is an autocrine/paracrine factor in the mechanism of Ang II-induced cardiac hypertrophy. In addition, Yamazaki et al. (7) found that stretch induced a rise in the concentration of ET-1 in the culture medium, where it is constitutively secreted from cardiomyocytes together with an increase in NHE-1 activity. The same authors showed that NHE-1 inhibition partially attenuated the stretch-induced mitogen-activated protein kinase activation. Therefore, our main contribution was to demonstrate the existence of a stretch-triggered autocrine/paracrine release of Ang II/ET leading to NHE-1 activation in an adult cardiac multicellular preparation (1-3). This finding allowed us to propose the hypothetical scheme depicted in Figure 1 important to emphasize that little or no change in pH i is detected when the stimulating effect of stretch, exogenous Ang II or ET-1 on NHE-1 is studied in the presence of bicarbonate buffers (1-3,42-44). The explanation for the lack of change in pH i can be found in the fact that growth factors like Ang II and ET simultaneously activate at least two opposing pH i -regulatory mechanisms: the alkalinizing NHE-1 and the acidifying Na ] i that follows NHE-1 activation. Therefore, NHE-1 activation can be detected as a pH i increase only if bicarbonate is absent from the medium. We emphasize this point because the absence of changes in pH i after growth factor stimulation in bicarbonate media is not widely recognized, though it was reported by Ganz et al. (47) in 1988 in mesangial cells and a call for attention was published by Thomas (48) in a letter to Nature one year later. More recently, Shafer et al. (8) demonstrated that the hypertrophic response of cardiomyocytes to α-and β-adrenergic stimulation requires NHE-1 activation but not cellular alkalization. In summary, although there is much evidence to suggest a direct correlation between activation of cellular acid extrusion mechanisms and proliferation, there is enough evidence to suggest that proliferation can occur without changes in pH i , and that changes in pH i do not necessarily induce proliferation (8,47,50,51). In human fibroblasts, bradykinin activates NHE-1 but does not influence cell proliferation (52). Regarding growth and viability in NHE-deficient mutants, there is no agreement in the literature. While some authors report that these animals can grow at normal rate (53), others have shown that NHE-1 -/-mice exhibit growth retardation and are subject to slow-wave epilepsy (54-56). -exchanger in preventing intracellular alkalization after myocardial stretch is better visualized by repeating the intervention in a bicarbonate medium before and after inhibition of the anion-exchanger with specific antibodies (see Figure 3) ] i -independent and protein kinase C-dependent pathway by direct stimulation of NCX; and c) a prolongation of the action potential duration. All of them appear to be contributing in concert after stretch. However, the [Na + ] iindependent pathway seems to contribute to the mechanism only after the primary participation of the [Na + ] i -dependent pathway, which appears to be a mandatory step (44).
The fact that Ang II triggers the beginning of the cascade of events leading to the show force response has not been confirmed by many authors in all their steps. Activation of the NHE-1 after stretch has been confirmed for different species by several authors (2,10,43,68,69). However, the pathway leading to its activation is controversial. The release of Ang II and activation of the AT 1 receptors by stretch proposed by us in rat and cat (1-3), though reported in isolated rat myocytes (40,70), was not confirmed by other investigators in ferret multicellular preparations (71). The role played by ET, the second step in the chain of events, has been reported by Calaghan and White in ferret (71) and by us in rat (2) and cat (1,3), but was not found by von Lewinski et al. in rabbit (72) or failing human myocardium (69). Whether the discrepancies are a matter of species differences is not apparent to us yet, but in any case, they leave open the possibility that under different experimental conditions some other mechanisms may be triggered after stretch. In this regard, other report by Calaghan and White (68) shows activation of stretch-activated channels in addition to the NHE-1 after myocardial stretch; Isenberg et al. (73) proposed that myocardial stretch increases [Na Another important aspect to be considered to clarify the failure of detecting if ET is participating in the slow force response to stretch is to analysing the pharmacological intervention used to prove it. In this regard, Endoh et al. have clearly shown that high doses of the non-specific ET receptor antagonist TAK044 were necessary to prevent the inotropic effect of ET in the myocardium (75) . In our hands, either TAK044 or the selective ETA receptor antagonist BQ123 blunted the slow force response (2,3). However, if based on the works of Calaghan and White (71) and our own results (1-3) the role of ET after stretch is accepted in addition to the well known fact that Ang II induces release/formation of ET as shown in different studies by us (42, 45, 76, 77) and others (41,78-89), the rationale to accept our proposed chain of events seems to be plausible.
Regarding the identification of the ET isoform (s) that could be participating after stretch, experiments in cat papillary muscles from our own laboratory demonstrated an increase in ET-3 mRNA after stretch (6). However, we should bear in mind that Tamamori et al. (90) presented evidence, at least in cultured neonatal cardiomyocytes, that ET-3 triggers the synthesis and release of ET-1 that probably mediates hypertrophic response. Therefore, though speculative, we should consider the possibility that the stretch of multicellular preparations triggers ET-3 release, which in turn increases the release/formation of ET-1. This complex mechanism and species-dependent differences may explain the discrepancies found in the signaling pathway leading to NHE-1 activation by stretch.
We can state that myocardial stretch-induced NHE-1 activation and the role of NCX in increasing Ca 2+ transient are confirmed facts. Considering the results of different investigators and ours (1-3,5,43,68) together with those from the experiments in isolated neonatal cardiomyocytes (10), we can conclude that NHE-1 activation induced by myocardial stretch constitutes a relevant intracellular signal. This signaling pathway can be also evoked by equipotent doses of exogenous Ang II or ET-1 (42).
THE SLOW FORCE RESPONSE IS THE MECHANICAL COUNTERPART OF THE AUTOCRINE/PARACRINE MECHANISM TRIGGERED BY STRETCH AND MAY EXPLAIN THE ANREP's PHENOMENON
It is well known that two consecutive phases characterize the increase in force after myocardial stretch: One immediate and the slow force response. The initial rapid change in force is induced by an increase in myofilament Ca 2+ responsiveness without changes in the Ca 2+ transient whose underlying mechanisms are beyond the scope of this review. The slow force response, in turn, is due to a progressive increase in the Ca 2+ transient without changes in myofilament Ca 2+ responsiveness (2,63,91) that appears to result from the autocrine/paracrine mechanism described in the previous section. While the initial change in force after stretch seems to express Frank-Starling mechanism, the slow force response may conceivably be the expression of Anrep's phenomenon.
In 1912, Von Anrep (92) observed that when aortic pressure was elevated, ventricular volume initially increased and then declined to the starting volume. It appeared to him that an influence operating soon after myocardial dilatation caused an increase in myocardial contractility. His interpretation was that perhaps, the decrease in the flow to the adrenal glands induced the release of catecholamines and the consequent positive inotropic effect. In 1959, experiments by Rosenblueth et al. (93) indicated that an increase in coronary perfusion pressure was not necessarily concomitant with the return of the heart to its initial volume. In 1960, Sarnoff et al. (94) coined the term "pressure-induced homeometric autoregulation" to define the decrease in left ventricular end diastolic volume that follows an increase in diastolic volume due to a sudden increase in afterload. On the other hand, since the experiments of Sarnoff et al. (94) were performed in isolated hearts, the study served to rule out the possibility of a role played by catecholamines in the described phenomenon. Interestingly, Sarnoff defined as "homeometric autoregulation" a phenomenon occurring in an organ which was not attributable to an influence by nerves or chemicals in its vicinity, paving the way for the idea of an autocrine/paracrine mechanism after cardiac stretching (94) . The existence of a real change in contractility during the homeometric autoregulation was challenged by the possibility of changes in coronary blood flow distribution (95). However, in 1973 Parmley and Chuck (96) reproduced for the first time the contractile effect of stretch in isolated strips of ventricular myocardium. They showed that when the length of the muscle was increased, there were corresponding rapid and slow increases in the developed force. Since the slow force response to the change in length was still present in isolated muscles from animals treated with reserpine, those authors also ruled out the possibility of catecholamines released by nerve endings as having a role in the mechanism.
We and other authors have provided evidence that activation of NHE-1 after stretch participates in the development of slow force response (2,3,43,68,69), however, there is no agreement in that the release of preformed Ang II mediates this activation (2,3,40,70,71). Ang II is an octapeptide acting through its own G coupled receptors AT1 and AT2. Gαqβγ activated by either Ang II or ET-1 targets the NHE through extracellular signalregulated protein kinases 1/2 (ERK1/2)-p90 ribosomal S6 kinase (p90rsk). We showed that the slow force response was abolished by AT1 receptors blockade (2,3,97) but not by AT2 receptors blockade (97) as shown in Figure 6A . These results support the notion that Ang II is released after stretch and triggers the intracellular signaling pathways leading to slow force response. Furthermore, a significant increase in ERK1/2 and p90rsk kinases phosphorylation can be detected after 15 minutes of stretch, effects that are both cancelled by AT1 receptors blockade with losartan as shown in Figure 6B (97) . Finally, inhibition of MEK (a kinase that is upstream of ERK1/2 and downstream of RAS kinases) by PD98059 abolished slow force response to stretch ( Figure 6C ).
ROLE OF ROS AFTER STRETCH
Ang II and ET-1 are well known activators of the Nicotinamide-Adenine Dinucleotide Phosphate (NADPH) oxidase (98-100) and through this action it has been reported the phenomenon called "ROS-induced ROSrelease", by which a small amount of ROS activates a greater ROS production from the mitochondria (101, 102) . The possibility that this mechanism may be acting in the chain of events following stretch was examined. Figure 7A shows that stretch -in addition to its mechanical effectinduced an increase in intracellular ROS formation of approximately 30% above baseline levels. Furthermore, scavenging of ROS by MPG or EUK8 inhibited both stretch-induced increase in ROS ( Figure 7A ) and slow force response ( Figure 7B ). We also found that the scavenging of ROS inhibited the increase in (Na + ) i that occurs in response to the stretch ( Figure 7C ).We may , which may open the ATP-sensitive mitochondrial potassium (mKATP) channels and produce a larger amount of ·O 2 -responsible for generating the slow force response. Therefore, if these assumptions were correct, the slow force response should be abolished by either NADPH oxidase inactivation or blockade of mKATP channels. As shown in Figure 8A , slow force response was abolished after inhibition of NADPH oxidase inhibition (apocynin or diphenyleneiodonium chloride) or after blockade of mKATP channels (5-hydroxydecanoate or glybenclamide). The NHE-1-induced increase in (Na + ) i accompanying slow force response was also abolished by these interventions ( Figure 8B ).
When ·O 2 -production was augmented in cat cardiac slices by Ang II, the effect was abolished by AT1 receptors blockade (losartan), ROS scavenging (N-(2-mercaptopropionyl)-glycine, MPG), NADPH oxidase inhibition (apocynin) and mKATP channels blockade (5-hydroxydecanoate or glybenclamide) as shown in Figure 9 .
NHE-1 ACTIVATION, THE MECHANICAL EFFECT AND MYOCARDIAL HYPERTROPHY
The possible link between slow force response to stretch and myocardial hypertrophy is supported by the fact that an enhanced activity of NHE-1 -the cause of the slow force response-is detected in several models of cardiac hypertrophy and, consistent with this, the specific blockade of NHE-1 has been shown to regress cardiac hypertrophy effectively in different models In 1995 enhanced activity of NHE-1 was reported in the hypertrophied myocardium of SHR (11,12). The hyperactivity of NHE-1 has been described in several tissues other than the myocardium, like in hypertensive humans and experimental animal models (104) (105) (106) . Experiments in our laboratory showed that hyperactivity of NHE-1 in the myocardium of the SHR was not accompanied by an increase in pH i , since there was a simultaneous activation of the acidifying Cl --HCO 3 -exchanger (12). We also reported that the NHE-1 increased activity in this model was the result of a protein kinase Cdependent post-translational modification of the exchanger (107) . It was further hypothesized that the inhibition of the antiporter activity could regress and/or prevent the development of hypertensive hypertrophy. Kusumoto et al. (13) proved that NHE-1 was upregulated after myocardial infarction and that the specific inhibition of this exchanger with cariporide decreased hypertrophy and remodeling in these hearts. Experiments from our own laboratory demonstrated that myocardial hypertrophy of spontaneously hypertensive rats (SHR) regressed after 1-month cariporide treatment (Figure 10 ) without significantly changing the arterial pressure (14). In addition, we reported that chronic NHE-1 blockade normalized the enhanced interstitial fibrosis of these hypertrophic hearts, but this effect took longer to occur compared to the regression of myocytes size (108) (Figure  11 ), possibly as a reflection of lower turn-over rate of collagen (109).
The precise mechanism by which NHE-1 inhibition prevents hypertrophy is still unknown, though a number of pathways have been proposed (110) . As there is evidence that calcineurin plays a key role in many pathological models of cardiac hypertrophy (111-117), we recently investigated its participation in the signaling pathway involved in the regression of cardiac hypertrophy induced by NHE-1 inhibition. We analyzed the expression of β-isoform of calcineurin A (CnAβ) as an indication of calcineurin activity. The nuclear abundance of NFAT in the left ventricular myocardium of untreated SHR, treated SHR and normotensive rats was measured as a confirmation of calcineurin activation. CnAβ expression and NFAT nuclear abundance are augmented in the hypertrophied myocardium of untreated SHR, compared with the normotensive rats, and that the regression of cardiac hypertrophy induced by NHE-1 inhibition normalizes both (Figure 12) (118) . An increased activity of calcineurin in the myocardium of the SHR, and its suppression by the treatment with Ca 2+ channel blockers has been previously reported (117) . This was the first report showing that the regression of cardiac hypertrophy caused by NHE-1 inhibition, which is independent from any change in blood pressure, is accompanied by normalization of CnAβ expression and NFAT nuclear abundance.
Even though we have provided evidence that a decrease in CnAβ and nuclear NFAT expression takes place during the regression of cardiac hypertrophy induced by NHE-1 inhibition, we cannot rule out the possibility of additional effects of the pharmacological interventions. It has been proposed that cariporide might exert effects at the mitochondrial level (29, [119] [120] [121] .
The link between NHE-1 activity and myocardial growth has been established for several neurohumoral models of cardiac hypertrophy. An up-regulation of NHE-1 was reported in cardiac hypertrophy and failure model of the β 1 -adrenergic receptor transgenic mice (15). The inhibition of this exchanger prevented the development of cardiac hypertrophy and fibrosis, suggesting that NHE-1 was essential for the detrimental cardiac effects of chronic β 1 -receptor stimulation in the heart (15). Similarly, cardiac hypertrophy induced in rats by chronic isoproterenol administration was prevented by inhibition of NHE-1 (16). On the other hand, we have also demonstrated that three different antihypertensive pharmacological interventions with different mechanisms of action (nifedipine, a Ca 2+ channel blocker; enalapril, an inhibitor of angiotensin converting enzyme; and losartan, an AT 1 receptor blocker) caused the normalization of myocardial NHE activity, regression of cardiac hypertrophy, and decrease of arterial pressure in SHR (122) . However, for a similar reduction in systolic blood pressure level and NHE activity, losartan induced the largest regression of cardiac hypertrophy. Even though these results give support to the hypothesis that an increased myocardial tension is determining intracellular signals having common end points on the antiporter activity and cellular growth, they also suggest that the eventual recruitment of additional intracellular pathways may be playing a role in the hypertrophic response.
The critical role of NHE-1 and/or [Na + ] i in the development of myocardial hypertrophy has been demonstrated in many different experimental models, like those mentioned below: 1) Hypertrophied hyperthyroid hearts show enhanced NHE-1 activity and when exposed to acute ischemia, they accumulate more Na + than the control non-hypertrophied hearts (17). These changes were prevented by NHE-1 inhibition (17). Furthermore, it has been demonstrated that thyroid hormone, by the interaction of its receptor with the NHE-1 promoter increases the expression of NHE-1 (123) .
2) In patients with end-stage renal disease and secondary hyperparathyroidism as well as in patients with primary hyperparathyroidism, a strong correlation between cardiac hypertrophy and serum parathyroid hormone levels has been reported (124) (125) (126) . This correlation was shown to be even much stronger than that between Ang II and hypertrophy (126) . In addition, a direct evidence that parathyroid hormone improves hypertrophy was also reported (127) . Though controversial (18,128), a stimulatory effect of parathyroid hormone on NHE-1 has been described; therefore, it is tempting to speculate about the possible involvement of the antiporter in the signaling pathway evoked by parathyroid hormone in the genesis of cardiac hypertrophy. On the other hand, low sodium plasma levels were detected in patients with NYHA class III-IV heart failure and high levels of parathyroid hormone (129) . The resulting misbalance of the Na + /Ca 2+ may in turn be a factor to consider in the development of cardiac hypertrophy. hypertrophy and elevated (Na+)i were prevented by the NHE-1-specific inhibitor EMD87580 as well as the aldosterone antagonist spironolactone (19). Similar results were obtained in uninephrectomized rats exposed to deoxycorticosterone acetate/salt, in which cariporide treatment completely inhibited hypertrophy and NHE-1 upregulation (20). 4) Recently a very interesting paper reported that cardiac hypertrophy of atrial natriuretic peptide receptor-deficient mice was accompanied by an increased activity of NHE-1, which thereby increased [Ca 2+ ] i (21). Those authors showed that these alterations were normalized by chronic treatment with the NHE-1 inhibitor cariporide. These results are in line with the report by Tajima et al. (130) demonstrating that atrial natriuretic peptide inhibits NHE-1 activity. 5) Emerging evidence indicates that leptin -a protein encoded by the obesity gene-is linked to cardiac hypertrophy (23-25). Interestingly, leptin has been reported to activate NHE-1 through a protein kinase Cdependent pathway (22). Moreover, it has been reported that leptin elevates ET-1 levels and, though speculative, this may be the pathway involved in NHE-1 stimulation (25). Furthermore, a recent report by Karmazyn's group implicated leptin as a mediator of hypertrophic effects of Ang II and ET-1 in cultured neonatal ventricular myocytes (24). 6) In right ventricular hypertrophy due to monocrotalineinduced pulmonary artery injury, myocardial NHE-1 expression was enhanced. As a consequence, both hypertrophy and NHE-1 up-regulation were abrogated by cariporide treatment (26). 7) When the sarcolemmal NHE-1 activity from normal unused human donor hearts was compared with that of recipient hearts with chronic end-stage heart failure exhibiting various degrees of hypertrophy, a significantly greater NHE-1 activity was detected in human hypertrophied myocytes (27).
As mentioned before, an enhanced activity of NHE-1 may be the result of an increased expression of the exchanger, an increased turnover of functional units, or a combination of both alternatives. In line with this, the reviewed models clearly exhibited cases of enhanced NHE-1 activity due to up-regulation, post-translational modification, or a combination of both. In either case, the hyperactivity of NHE-1 was linked to cardiac hypertrophy.
Interestingly, whereas chronic NHE-1 inhibition with cariporide in the whole animal induces up-regulation of the exchanger (131), the normalization of its previously augmented expression has been reported after chronic NHE-1 inhibition (15,16,21,26) . Nevertheless, several aspects deserve further investigation to clarify the precise mechanism by which NHE-1 is involved in the development of cardiac hypertrophy and the possible link with other mechanisms of the intracellular hypertrophic program, like Wnt/Frizzled signaling pathways (132, 133) .
In line with the experiments reported by Kusumoto et al. (13) showing that NHE-1 inhibition decreased hypertrophy and remodeling after myocardial infarction, we have recently reported that post-myocardial infarction hypertrophy and fibrosis were reduced after phosphodiesterase 5A inhibition by sildenafil, the 
